• India: Novartis Tries to Weaken Patent Laws That Protect Patients
  • What Novartis says…and why it’s wrong
  • Novartis’s excuses fail once again
alerte
Gefährlicher Patentstreit [videoportal]
ACT UP-BASEL

Novartis sues Indian Government and threatens access to care of millions patients around the world
While stockholders were leaving the AGM, activists chanted slogans highlighting the consequences of the Novartis case which will be heard in a few weeks by the Indian Supreme Court for patients around the world. At the demonstration, videos from patients and concerned individuals from Asia, America, Europe, Russia and Africa denouncing Novartis’ attack on generic medicines were screened. Messages from across the globe to Novartis and its shareholders included “Novartis, drop your case!” as patients asked in their videos “How can I have access to care with the highest prices imposed by Novartis?” Through this case before the Indian Supreme Court, Novartis challenges a key provision in the Indian Patents Act, 1970 - the last defence against Big Pharma’s greed and the avenue for access to (...)

ACT UP-BASEL : WHO ARE WE ?

Act Up Basel acts to promote universal access to affordable medicines of assured quality. Whether it is the developed world or developing countries, access to treatment and care is an issue that concerns each one of us. From major pandemics (tuberculosis, HIV/AIDS, malaria), to neglected diseases (chagas, sleeping sickness, etc.), to chronic diseases (cancers, diabetes, respiratory diseases, cardiovascular or neurological), many people through the world spend disproportionate amounts to access expensive treatment and care. Research for rare diseases (genetic disorders or "tropical") is neglected by big pharmaceutical companies and often whole populations are ignored because they do not constitute markets profitable enough for the pharmaceutical industry to pay attention to. . In (...)

Novartis lies threaten our lives : Act Up-Basel launched to declare the war on pharma

BASEL, SWITZERLAND – Tomorrow in New Delhi, the next hearing of the case brought by the Basel-based pharmaceutical firm Novartis against the Indian government is scheduled to take place. Novartis is challenging a critical health safeguard – section 3(d) of Indian Patents Act in the Supreme Court of India – to secure monopoly control over its life-saving cancer medicine, Glivec. In essence, Novartis wants section 3(d), which requires stringent evidence of proof of significantly enhanced therapeutic efficacy if a modification of an existing pharmaceutical entity is to receive new patent protection, to be reinterpreted to allow routine “ever-greening” of minor modifications to existing medicines resulting in additional 20-year patent monopolies. If Novartis wins this case, the ability of (...)
SPIP | Site Map | Follow-up of the site's activity RSS 2.0 |